Literature DB >> 7020046

The role of complement in the host's defense against Streptococcus pneumoniae.

J A Winkelstein.   

Abstract

In recent years there has been a growing realization that the complement systems plays an important role in the host's defense against infection and that it plays an especially critical role in both natural and acquired immunity to Streptococcus pneumoniae. The terminal components of the complement system, C3-C9, are responsible for most protective functions of the complement system. However, in order to subserve their protective functions, C3-C9 must first be activated. In vitro studies have shown that pneumococci are able to activate the terminal components of complement, C3-C9, by at least two different mechanisms, the classical and alternative pathways. Regardless of the pathway of their activation, C3-C9 produce anaphylatoxic, chemotactic, and opsonic activities in serum, each of which has the potential to play an important protective role in pneumococcal infections. Studies with experimental animals and the experience gained from study of complement deficiencies in humans have each fulfilled the promise of the in vitro studies by demonstrating that the complement system plays a biologically significant role in vivo in the host's defense against S. pneumoniae.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7020046     DOI: 10.1093/clinids/3.2.289

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  43 in total

1.  Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells.

Authors:  S Romero-Steiner; D Libutti; L B Pais; J Dykes; P Anderson; J C Whitin; H L Keyserling; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

2.  Streptococcus pneumoniae phosphotyrosine phosphatase CpsB and alterations in capsule production resulting from changes in oxygen availability.

Authors:  K Aaron Geno; Jocelyn R Hauser; Kanupriya Gupta; Janet Yother
Journal:  J Bacteriol       Date:  2014-03-21       Impact factor: 3.490

3.  Initiation and synthesis of the Streptococcus pneumoniae type 3 capsule on a phosphatidylglycerol membrane anchor.

Authors:  Robert T Cartee; W Thomas Forsee; Janet Yother
Journal:  J Bacteriol       Date:  2005-07       Impact factor: 3.490

4.  Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H.

Authors:  C Neeleman; S P Geelen; P C Aerts; M R Daha; T E Mollnes; J J Roord; G Posthuma; H van Dijk; A Fleer
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

5.  Streptococcus pneumoniae type 14 polysaccharide-conjugate vaccines: length stabilization of opsonophagocytic conformational polysaccharide epitopes.

Authors:  C A Laferriere; R K Sood; J M de Muys; F Michon; H J Jennings
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

6.  Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines.

Authors:  Jan T Poolman; Carl E Frasch; Helena Käyhty; Pascal Lestrate; Shabir A Madhi; Isabelle Henckaerts
Journal:  Clin Vaccine Immunol       Date:  2009-11-04

7.  Position of O-Acetylation within the Capsular Repeat Unit Impacts the Biological Properties of Pneumococcal Serotypes 33A and 33F.

Authors:  Brady L Spencer; Jamil S Saad; Anukul T Shenoy; Carlos J Orihuela; Moon H Nahm
Journal:  Infect Immun       Date:  2017-06-20       Impact factor: 3.441

8.  Correlation of serum opsonins with in vitro phagocytosis of Streptococcus pneumoniae.

Authors:  D S Chudwin; S G Artrip; A Korenblit; G Schiffman; S Rao
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

9.  Measurement of modulation of mouse complement levels in vivo, utilizing a microtiter hemolytic assay.

Authors:  K L White; A C Anderson
Journal:  Agents Actions       Date:  1984-12

10.  Streptococcus pneumoniae resistance to complement-mediated immunity is dependent on the capsular serotype.

Authors:  Catherine Hyams; Jose Yuste; Katie Bax; Emilie Camberlein; Jeffrey N Weiser; Jeremy S Brown
Journal:  Infect Immun       Date:  2009-11-30       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.